A Randomized, Open-Label, 2x2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg tablet and 2x Lu AA21004 10 mg tablets in Healthy Adult Subjects

Next Previous
Trial Profile

A Randomized, Open-Label, 2x2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg tablet and 2x Lu AA21004 10 mg tablets in Healthy Adult Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2018

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Anxiety disorders; Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Takeda Pharma

    • Most Recent Events

    • 26 Mar 2018 Planned End Date changed from 9 Sep 2018 to 5 Apr 2018.
    • 26 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 20 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top